Clinical Trial: Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07753720) titled 'Daily Tadalafil as Adjunctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dysfunction' on July 29.

Brief Summary: This randomized trial will compare daily tadalafil 5 mg as adjunct therapy versus monotherapy in men with on-demand PDE5 inhibitor-resistant erectile dysfunction. The study will evaluate changes in erectile function, treatment satisfaction, partner satisfaction, and safety over 12 weeks.

Study Start Date: July 30

Study Type: INTERVENTIONAL

Condition: Erectile Dysfunction Tadalafil

Intervention: DRUG: Tadalafil; Current on-demand PDE5 inhibitor

Tadalafil 5 mg orally once daily for 12 weeks plus ...